SKYRIZI

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 7d ago
• Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
  Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
  fiercebiotech · 27d ago
• MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
  MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
  fiercebiotech · 1mo ago
• AbbVie touts strong momentum for Skyrizi despite rising competition
  If AbbVie executives are bothered by growing threats to their immunology powerhouse, they aren't letting on. Earlier this year, analysts were wondering how the company’s blockbuster Skyrizi might f…
  endpoints · 2mo ago
• AbbVie shares pressured as Q2 I&I beat falls below investor expectations
  AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
  biospace · 2mo ago
• Chutes & Ladders—Legend CEO departs without successor in place
  Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
  fiercebiotech · 2mo ago
• ‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
  Caldera Therapeutics has struck a reverse merger with the publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the inflammatory bowel disease startup.
  fiercebiotech · 2mo ago
• Sarepta names former AbbVie R&D exec Michael Severino as next CEO
  After leaving Tessera Therapeutics earlier this month, Michael Severino will take over Sarepta Therapeutics as the biotech awaits two key regulatory decisions in Duchenne muscular dystrophy.
  biospace · 2mo ago
• Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
  Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
  biopharma_dive · 2mo ago
• Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
  The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
  biopharma_dive · 3mo ago